

Targeted DNA ADP-ribosylation triggers templated repair in bacteria and base mutagenesis in eukaryotes

Constantinos Patinios^{1*}, Darshana Gupta^{1*}, Harris V. Bassett^{1*}, Scott P. Collins², Charlotte Kamm¹, Anuja Kibe¹, Yanyan Wang¹, Chengsong Zhao³, Katie Vollen³, Christophe Toussaint¹, Kathryn M. Polkoff², Thuan Nguyen², Irene Calvin¹, Angela Migur¹, Ibrahim S. Al'Abri², Tatjana Achmedov¹, Alessandro Del Re¹, Antoine-Emmanuel Saliba^{1,4}, Nathan Crook², Anna N. Stepanova³, Jose M. Alonso³, Chase L. Beisel^{1,5@}

¹Helmholtz Institute for RNA-based Infection Research (HIRI), Helmholtz Centre for Infection Research (HZI), 97072 Würzburg, Germany

²Department of Chemical and Biomolecular Engineering, North Carolina State University, Raleigh, NC 27695, USA

³Department of Plant and Microbial Biology, North Carolina State University, Raleigh, NC 27695, USA

⁴Institute of Molecular Infection Biology, University of Würzburg, 97072 Würzburg, Germany

⁵Medical Faculty, University of Würzburg, 97072 Würzburg, Germany

@Correspondence: chase.beisel@helmholtz-hiri.de (to: C.L.B.)

1 **ABSTRACT**

2 Base editors create precise genomic edits by directing nucleobase deamination or removal
3 without inducing double-stranded DNA breaks. However, a vast chemical space of other
4 DNA modifications remains to be explored for genome editing. Here, we harness the
5 bacterial anti-phage toxin DarT2 to append ADP-ribosyl moieties to DNA, unlocking distinct
6 editing outcomes in bacteria versus eukaryotes. Fusing an attenuated DarT2 to a Cas9
7 nickase, we program site-specific ADP-ribosylation of thymines within a target DNA
8 sequence. In tested bacteria, targeting drives efficient homologous recombination in tested
9 bacteria, offering flexible and scar-free genome editing without base replacement nor
10 counterselection. In tested eukaryotes including yeast, plants and human cells, targeting
11 drives substitution of the modified thymine to adenine or a mixture of adenine and cytosine
12 with limited insertions or deletions, offering edits inaccessible to current base editors.
13 Altogether, our approach, called append editing, leverages the addition of a chemical moiety
14 to DNA to expand current modalities for precision gene editing.

15 INTRODUCTION

16 In the expanding field of genome editing, targeting chemical modifications to a specific DNA
17 sequence offers an effective way to create precise genomic edits without relying on double-
18 stranded DNA breaks¹⁻³. These modifications are installed at selected sites by base editors
19 (BEs) comprising an enzymatic DNA domain and a programmable DNA binding protein.
20 After the BE acts on recognized bases within a selected target site, the modified bases then
21 change identity, resulting in a permanent genetic substitution. As this process does not
22 actively generate double-stranded DNA breaks at the target site, unintended and possibly
23 harmful genetic alterations such as random insertions or deletions (indels), chromosomal
24 abnormalities, chromothripsis are avoided^{1,4}. To date, BEs have been applied in all three
25 domains of life^{5,6} including DNA-containing organelles like mitochondria⁷, can convert each
26 of the four bases⁶, and have recently entered clinical use⁸.

27 Within these advances, BEs have consistently relied on DNA deaminases to remove
28 an amino group, changing the base's perceived identity, or DNA glycosylases to remove the
29 entire base, driving the base's replacement via base excision repair^{2,9}. While such
30 "subtractive" DNA modifications represent powerful means to elicit precise gene edits, what
31 remains unexplored is the impact of "additive" DNA modifications. Extensive work in DNA
32 repair has shown that appended chemical moieties can elicit diverse DNA repair pathways,
33 such as homologous recombination, translesion synthesis, nucleotide-excision repair or
34 Fanconi anemia repair, extending well beyond base-excision repair¹⁰⁻¹². However, the
35 programmable addition of chemical moieties to DNA for gene editing remains to be explored.

36 One promising starting point derives from the DNA ADP-ribosyltransferase protein
37 DarT2¹³. DarT2 is part of the DarT2/DarG toxin-antitoxin system recently associated with a
38 growing collection of anti-phage defenses (**Fig. 1a**)¹⁴. As the system's toxin, DarT2 appends
39 a single ADP-ribosyl moiety to the N3 position of thymine in single-stranded DNA using the
40 metabolic cofactor NAD⁺ as a substrate¹⁵. The antitoxin DarG protein catalytically removes
41 the appended ADP-ribosyl moiety and serves as a DNA mimic that binds DarT2¹⁶. During a
42 phage infection, DarG is inactivated through an unknown mechanism, and DarT2 begins

43 ADP-ribosylating DNA within the bacteriophage and host genome¹⁴. An appended ADP-
44 ribosyl moiety interferes with DNA replication, which can block bacteriophage replication and
45 induce cellular growth arrest. In *Escherichia coli*, growth arrest could be partially relieved
46 through bypass via RecF-mediated homologous recombination with the sister chromatid
47 followed by removal through nucleotide-excision repair (**Fig. 1b**)¹⁷. Critically, this mode of
48 repair contrasts with traditional base editing in this bacterium^{18,19}, suggesting that the
49 installation of an ADP-ribosyl moiety could unlock distinct types of genome edits. Here, we
50 explore such an approach, which we call append editing. As we append an ADP-ribosyl
51 (ADPr) moiety to thymine, the approach can be abbreviated as ADPr-T append editing
52 (ADPr-TAE).

53

54 RESULTS

55 CRISPR-guided ADP-ribosylation drives homologous recombination in *E. coli*

56 To explore the outcome of targeted DNA ADP-ribosylation, we selected the previously
57 characterized DarT2 from enteropathogenic *Escherichia coli* (EPEC) O127:H6 str.
58 E2348/69¹⁷. The EPEC DarT2 was shown to ADP-ribosylate single-stranded DNA at the
59 third position in a 5'-TYTN-3' motif (Y = C/T), with the fourth position biased against a G¹⁷.
60 Paralleling its growth-inhibitory effects *in vivo*, this DarT2 blocked extension by the large
61 fragment of *E. coli*'s DNA Polymerase I *in vitro* from a single-stranded (ss)DNA template with
62 the recognition motif (5'-TCTC-3'), whereas extension was unhindered with a mutated motif
63 (5'-ACTC-3') or with DarT2 containing the inactivating E170A mutation (dDarT2) (**Figs. 1c-d**
64 **and S1**)¹⁷.

65 To direct DNA ADP-ribosylation, we fused DarT2 to the N-terminus of the PAM-
66 flexible (5'-NNG-3') *Streptococcus canis* Cas9 (ScCas9) (**Fig. 1e**)²⁰. Directing the DarT2-
67 Cas9 fusion to a target sequence through a designed single-guide (sg) RNA would localize
68 DarT2 to the non-target strand displaced during R-loop formation (**Fig. 1e**). If the non-target
69 strand contains a 5'-TYTN-3' motif accessible to DarT2, then the target thymine within the
70 motif would be ADP-ribosylated and serve as a block to DNA replication. As wild-type DarT2

71 would arrest cell growth through genome-wide ADP-ribosylation, we included a previously
72 reported spontaneous G49D mutation in the NAD⁺-binding loop helix (DarT2^D) exhibiting
73 reduced cytotoxicity¹⁷. To promote repair through a provided DNA template rather than the
74 sister chromatid, we used a nickase version of Cas9 (D10A) that only cleaves the target
75 strand and provided a plasmid-encoded repair template with ~500-bp homology arms
76 flanking the intended edits.

77 As a simple readout of homologous recombination, we introduced a premature stop
78 codon into a chromosomally integrated kanamycin resistance gene in *E. coli* strain MG1655
79 (**Fig. 1f**). The premature stop codon overlaps with an ScCas9 target containing the 5'-TTTC-
80 3' DarT2 motif and a PAM sequence, while a provided repair template with ~500-bp
81 homology arms introduces mutations that revert the premature stop codon and remove the
82 DarT2 motif. As part of an editing assay, plasmids encoding the editor, sgRNA, and repair
83 template are transformed into *E. coli*, and colony counts are compared following editor
84 induction and plating with or without kanamycin.

85 To set a baseline, we applied dsDNA cleavage with Cas9, which is commonly used
86 for genome editing in bacteria²¹. As dsDNA cleavage principally removes cells that did not
87 undergo recombination, using Cas9 resulted in 66% kanamycin-resistant colonies and a
88 159-fold colony reduction compared to the non-targeting control ($p = 0.0002$, $n = 3$) (**Fig.**
89 **1g**). The nickase version of Cas9 did not deplete colony counts (3.6-fold increase relative to
90 the non-targeting control, $p = 0.02$, $n = 3$) but at the expense of fewer kanamycin-resistant
91 colonies (4%), in line with nicking being less cytotoxic but a poor driver of homologous
92 recombination. Binding DNA alone with a catalytically dead Cas9 (dCas9) exhibited similar
93 colony counts to nCas9 ($p = 0.07$, $n = 3$) and did not drive any measurable editing.

94 Turning to append editing with DarT2, the nCas9-DarT2^D fusion yielded 96%
95 kanamycin-resistant colonies, and negligible depletion in colony counts compared to its non-
96 targeting control (2.0-fold increase, $p = 0.25$, $n = 3$) (**Fig. 1g**). Both DNA ADP-ribosylation
97 and opposite-strand nicking were important, as conferring kanamycin resistance was less
98 effective with nicking alone (nCas9-dDarT, 0.16%, $p = 0.003$, $n = 3$) or ADP-ribosylation

99 alone (dCas9-DarT2^D, 38%, $p = 0.029$, $n = 3$) when compared to nCas9-DarT2^D. All
100 screened kanamycin-resistant colonies contained the intended edit (**Fig. S2**). Dart2^D still
101 conferred cytotoxicity, as cell counts were low even for the non-targeting controls and
102 increased upon deactivation of DarT2 (**Fig. 1g**), creating an opportunity to further attenuate
103 the toxin. Collectively, append editing with DarT2 drives homologous recombination with a
104 provided template in *E. coli*, yielded editing that outperformed traditional Cas9-based
105 approaches.

106

107 **Targeted ADP-ribosylation does not induce detectable base edits in *E. coli***

108 Our employed reporter assay requires homologous recombination to confer kanamycin
109 resistance. However, chemically modifying DNA bases can lead to single nucleotide edits as
110 demonstrated by BEs^{18,22}. We therefore asked whether append editing could drive editing
111 without antibiotic selection but also induce base mutagenesis. First, we repeated the *kanR*
112 reporter assay in the absence of kanamycin selection and performed amplicon sequencing
113 on the target site from liquid culture (**Fig. 1h**). Under targeting conditions, append editing
114 yielded 82% of total reads with the desired edit that drastically dropped with nicking alone
115 (0.9%), paralleling the fraction of kanamycin-resistant colonies (**Fig. 1g**). Of the remaining
116 reads, the few detected substitutions of the ADP-ribosylated thymine were not significantly
117 elevated in any sample ($F = 1.03$, $p = 0.39$, $df = 3$) (**Fig. S3**). As homologous recombination
118 could overshadow base editing, we performed the assay in the absence of the repair
119 template. However, the 16 screened colonies only yielded the original sequence (**Fig. S4**).
120 Therefore, append editing with DarT2 did not result in detectable base edits in *E. coli*, further
121 supporting sole triggering of homologous recombination.

122 Base editing can also occur at genomic sites unrelated to the target sequence
123 presumably through the DNA modification domain acting on DNA that is temporarily single-
124 stranded²³. Given the lack of obvious substitutions at the target site with append editing, we
125 hypothesized that DarT2 expression would not lead to such edits associated with BEs.
126 Culturing editor-expressing cells and performing whole-genome sequencing of three

127 individual clones (**Fig. 1i and Table S1**), a cytosine base editor (CBE) yielded the expected
128 C-to-T edits²³, with either three or eight edits in each clone. In contrast, the ADPr-TA editor
129 yielded no T-to-G edits and similarly few T-to-C edits as the CBE or no editor. One of the
130 three clones with the ADPr-TA editor yielded a single T-to-A edit, while none were observed
131 with the CBE or no editor. This one edit was associated with the 5'-TYTN-3' motif,
132 suggesting that base mutagenesis is possible but rare (**Table S1**). Thus, even a highly active
133 DarT2 that reduces cell viability (**Fig. 1g**) does not inherently drive base edits across the *E.*
134 *coli* genome.

135

136 **Attenuating DarT2 alleviates cytotoxicity without compromising homologous** 137 **recombination**

138 ADPr-TAE yielded high editing efficiencies, although the expressed DarT2^D exhibited strong
139 cytotoxicity (**Fig. 1g**). As the cytotoxicity was likely due to ADP-ribosylation of ssDNA across
140 the genome, we aimed to attenuate DarT2 without compromising localized ADP-ribosylation
141 and subsequent initiation of homologous recombination using structural insights and
142 sequence conservation (**Fig. 2a**). While the structure of EPEC DarT2 remains to be
143 experimentally determined, a crystal structure is available for the *Thermus* sp. 2.9 DarT2
144 sharing 34% amino-acid identity with EPEC DarT2¹⁵. Aligning this structure with the
145 AlphaFold-predicted structure of EPEC DarT2²⁴, we selected a subset of residues potentially
146 involved in binding the DNA recognition motif (M84, M86, R57, R92, R166) or potentially
147 flanking regions of the DNA strand not captured in the crystal structure (R193). The
148 positively charged arginines were mutated to uncharged alanine, while the methionines were
149 mutated to leucine to disrupt the coordinating sulfur while preserving the residue's
150 hydrophobicity and chain length. Testing these substitutions in combination with G49D as
151 part of the kanamycin-resistance reversion assay (**Figs. 1f**), we found that all improved cell
152 viability (**Fig. 2b**). At the same time, three of the mutations (M86L, R92A, R193A) maintained
153 the fraction of kanamycin resistant colonies comparable to the original G49D ($p = 0.77, 0.51$

154 and 0.27 respectively, $n = 3$) (**Fig. 2b**), representing candidates for further use with append
155 editing.

156 Viability was greatly enhanced across the single-substitution variants, yet DarT2 may
157 still exert target-independent ADP-ribosylation that could have more subtle effects on cell
158 growth and behavior. We therefore generated cells hypersensitive to ADP-ribosylation by
159 deleting the core repair gene *recA* to disable homologous recombination, and we assessed
160 cell growth when expressing each ADPr-TAE variant under non-targeting conditions (**Figs.**
161 **2c and S5**). While growth rates in exponential phase were similar (**Fig. S5**), we observed
162 marked differences in entry into stationary phase. In particular, amino acid substitutions that
163 previously compromised editing (M84L, R57A, R166A) yielded final turbidities paralleling the
164 inactivating E170A ($p = 0.35, 0.65, \text{ and } 0.22$ respectively, $n = 3$) (**Figs. 2d and S5**). In
165 contrast, substitutions that previously showed high editing efficiencies (M86L, R92A, R193A)
166 exhibited a final turbidity similar to G49D alone ($p = 0.99, 0.05, \text{ and } 0.17$ respectively, $n = 3$)
167 and lower than the E170A. We therefore combined the high editing mutations (M86L, R92A,
168 R193A) into a four-substitution version of DarT2, DarT2^{DLAA}. This version maintained cell
169 viability and a high frequency of kanamycin-resistant colonies (49%) in *E. coli* MG1655 (**Fig.**
170 **2b**). Moreover, in the *recA*-deletion strain, the append editor with DarT2^{DLAA} restored final
171 turbidity to approach that of the editor lacking ADP-ribosylation ($p = 0.09, n = 3$) (E170A)
172 (**Fig. 2d**).

173 By improving cell viability and growth in a strain in which homologous recombination
174 was fully disabled, the append editor with DarT2^{DLAA} afforded the opportunity to probe the
175 genetic basis of templated-mediated editing. Prior work on the cytotoxicity of DarT2^D in *E.*
176 *coli* revealed a key role by RecF and possibly nucleotide-excision repair¹⁷. However, the
177 involved DNA repair pathways as part of targeted ADP-ribosylation with opposite-strand
178 nicking could differ. Within the kanamycin-reversion assay (**Fig. 1f**), *recA* was essential for
179 editing and even showed some reduction in colony counts under non-targeting conditions
180 (**Fig. 2e**). Disrupting the RecBCD branch of recombination ($\Delta recB$) reduced viability but also
181 increased the frequency of kanamycin-resistant colonies, suggesting a role in survival in the

182 absence of recombination with the provided repair template. In contrast, disrupting the
183 alternative RecFOR recombination pathway ($\Delta recF$, $\Delta recO$) reduced editing relative to the
184 wild type (one-sided Welch's t-test, $p = 0.048$, 0.001 respectively, $n = 3$) but not viability for
185 *recF* (one-sided Welch's t-test, $p = 0.40$, $n = 3$), suggesting involvement in templated
186 recombination. Disrupting RecA-independent RecT recombination ($\Delta recT$) significantly
187 reduced both viability and editing (one-sided Welch's t-test, $p = 0.002$, 0.003 respectively, n
188 $= 3$), suggesting involvement in both survival and templated recombination. Finally, the DNA
189 repair exonuclease RecJ ($\Delta recJ$), mismatch repair ($\Delta mutS$), base excision repair ($\Delta xthA$)
190 and nucleotide-excision repair ($\Delta uvrA$) did not impact editing (one-sided Welch's t-test, $p =$
191 0.89 , 0.68 , 0.81 respectively, $n = 3$) or viability (one-sided Welch's t-test, $p = 0.87$, 0.24 ,
192 0.93 , $n = 3$) relative to the wild type. These findings implicate multiple recombination
193 pathways as part of ADPr-TAE in *E. coli*.

194

195 **Attenuated ADP-ribosylation enables flexible and non-cytotoxic genome editing in** 196 **bacteria**

197 Append editing with DarT2^{DLAA} efficiently reverted the premature stop codon in the
198 kanamycin-reversion assay. However, the reliance on homologous recombination lends to a
199 much broader range of edits in different genes and bacteria. We therefore explored the
200 bounds of ADPr-TA editing. For simplicity, editing was performed around the premature stop
201 codon in the kanamycin-reversion assay. When testing edits beyond reversion of the stop
202 codon, editing efficiency was determined without kanamycin selection by assessing the
203 target-site size or sequence of individual colonies.

204 Beginning with the homology arms, condensing their length from ~500 to 100 bp
205 reduced the frequency of kanamycin resistance from 86% to 28%, while arm lengths of 50
206 bp and below exhibited virtually no kanamycin resistance (**Fig. S6**). Continuing with ~500-bp
207 homology arms, we tested increasingly larger replacements, deletions and insertions (**Fig.**
208 **2f-h**). Replacements extending up to 60 bp upstream or downstream of the target site or 91
209 bp spanning the target site were present in 80-100% and 50-75% of screened colonies,

210 respectively, either as complete or partial conversions (**Figs. 2g and S7**). Separately,
211 deletions up to 91 bp were present in 90-100% of screened colonies, albeit with a high
212 fraction of partial conversion with the largest deletion. Finally, insertions of 10 bp and 100 bp
213 were present in 100% and 50-90% of screened colonies, respectively. No colonies contained
214 an insertion of 500 bp (**Fig. S8**), indicating an upper limit to recombination. Editing was not
215 limited to this target site in *E. coli*, as we could introduce substitutions at four additional
216 targeted genes in *E. coli* (**Fig. S9a**) as well as one targeted gene in the pathogen *Salmonella*
217 *enterica* (**Fig. S9b**). Collectively, ADPr-TAE can introduce ranging replacements, insertions,
218 and deletions in bacteria without sacrificing viability.

219

220 **Targeted ADP-ribosylation preferentially drives base mutagenesis in yeast and plants**

221 Given that append editing drove templated recombination in bacteria, we asked whether
222 eukaryotes would undergo similar editing outcomes. Beginning with baker's yeast
223 *Saccharomyces cerevisiae* cultured as haploids, we transformed plasmids encoding the
224 DarT2^{D_{LAA}} append editor, an sgRNA and a repair template with ~250-bp homology arms to
225 introduce a premature stop codon as part of six substitutions in the *FCY1* gene. Individual
226 colonies were then screened based on Sanger sequencing of the target site (**Figs. 3a and**
227 **S10**). This approach resulted in 17% of screened colonies containing the templated
228 substitution (**Fig. 3b**). No edited colonies were obtained under non-targeting conditions or
229 with DNA nicking alone, affirming the necessity of targeted ADP-ribosylation.

230 Beyond templated recombination, we observed a distinct set of edits in 25% of
231 screened colonies: conversion of the ADP-ribosylated thymine into a different base (**Figs. 3c**
232 **and S10**). These base substitutions principally occurred at the thymine expected to undergo
233 ADP-ribosylation by DarT2, with the modified base becoming an A (67%) or a C (33%) (**Fig.**
234 **3c**). Homologous recombination and base mutagenesis represented mutually exclusive
235 repair outcomes, as removing the repair template enhanced the mutagenesis frequency
236 without altering the location and distribution of mutations (**Figs. 3c-d and S11**). Base
237 mutation was also observed when targeting sites within the genes *ALP1* and *JSN1*, albeit at

238 lower frequencies (**Fig. S12**). Thus, in yeast, append editing drives either homology-directed
239 repair or mutagenesis of the ADP-ribosylated thymine.

240 The outcomes of append editing in yeast represented a major deviation from what we
241 observed in tested bacteria and could reflect distinct editing outcomes in eukaryotes at large.
242 However, in contrast to higher eukaryotes, yeast engages in non-homologous end joining
243 less frequently and lacks poly-ADP-ribosyl polymerases involved in dsDNA break repair that
244 add and extend ADP-ribosyl groups on DNA ends^{25,26}. We therefore assessed the impact of
245 ADPr-TAE in the model plant *Nicotiana benthamiana*. As a simple and fast assay,
246 *Agrobacterium* constructs encoding the append editor are injected into *N. benthamiana*
247 leaves, and the type and frequency of edits are assessed via target amplicon sequencing
248 from transfected tissues (**Fig. 3e**). In this setup, no repair template was included given the
249 generally low frequencies of homologous recombination in this type of transfection assay in
250 plants²⁷. We also used the *Streptococcus pyogenes* Cas9 (SpCas9) given the availability of
251 existing constructs, and we fused DarT2^D, which did not result in any obvious morphological
252 changes.

253 Despite expectedly low transfection efficiencies, we could measure substitution of the
254 ADP-ribosylated thymine as the dominant outcome in 1.4% of reads targeting the *PDS1*
255 gene (**Fig. 3f-g**). The thymine was converted to the other three bases, but with a bias toward
256 A (59%) over C (19%) and G (22%). Testing two other target sites within *PDS1*, including
257 one containing multiple DarT2 motifs, resulted in similar mutagenesis of the ADP-ribosylated
258 T, with a bias toward A (**Figs. 3g and S13**). Indels were observed in targeting samples, but
259 at frequencies 6-80-fold lower than base mutagenesis (**Fig. S14**). Thus, append editing can
260 drive mutagenesis of the ADP-ribosylated base in both yeast and plants, reflecting distinct
261 editing outcomes from those we observed in bacteria.

262

263 **Targeted ADP-ribosylation drives base mutagenesis in human cells lacking TARG1**

264 As a final but important branch of eukaryotes, we sought to explore append editing in human
265 cells. Unlike yeast and plants, human cells possess an ADP-ribosyl deacylase TARG1 that

266 was previously shown to reversibly remove the ADP-ribosyl moiety appended to thymines by
267 DarT2 (**Fig. 4a**)²⁸. We therefore began by assessing ADPr-TAE in human cells with an intact
268 or disrupted *TARG1* gene (**Fig. S15**). Plasmid constructs encoding an SpCas9-based editor
269 and an sgRNA were transiently transfected into HEK293T cells, and editing was assessed
270 through next-generation sequencing of the target site in *EMX1* without sorting or selection of
271 transfected cells (**Fig. 4b**). An oligonucleotide repair template specifying a nine-base
272 substitution and four-base deletion was included to evaluate both homologous recombination
273 and base mutagenesis in parallel.

274 Using SpCas9 in HEK293T cells as a baseline, we observed matching extents of
275 templated edits (22%) and indels (32%), with no significant difference in the absence of
276 *TARG1* ($p = 0.99$ and 0.94 respectively, $n = 3$) (**Fig. 4c**). Nicking similarly generated a high
277 level of templated edits whether or not *TARG1* was intact (18%), but with minimal indels
278 (0.4%) due to the lack of dsDNA breaks. The append editor with DarT2^D also yielded
279 templated edits, with the editing frequency increasing from 7% to 10% by disrupting *TARG1*.
280 However, no significant differences were observed for append editors with the attenuated
281 DarT2^{DLAA} or with dDarT2 ($p = 0.32$ and 0.33 respectively, $n = 3$), suggesting that the
282 templated edits were driven primarily through DNA nicking rather than DNA ADP-
283 ribosylation.

284 At the same time, the ADPr-TA editor with DarT2^D yielded 9% base substitutions
285 specifically at the modified thymine within two overlapping DarT2 recognition motifs, but only
286 with *TARG1* disrupted (**Fig. 4c**). Base substitutions were negligible with DarT2^{DLAA} (0.2%) or
287 dDarT2 (0.3%), suggesting that higher levels of ADP-ribosylation were necessary to drive
288 editing (**Fig. 4c**). Indel frequencies for ADPr-TAE were slightly elevated over nCas9 with
289 *TARG1* disrupted (1.5% vs. 0.9%, $p = 0.03$, $n = 3$) but still 22-fold lower than that observed
290 with Cas9 (33%) (**Fig. 4c**), indicating that the principal repair outcome of ADP-ribosylation
291 and opposite strand nicking is base mutagenesis. We also observed a low frequency of
292 larger deletions that were elevated with DNA nicking (**Fig. S16**), paralleling observations with

293 BEs²⁹. Thus, ADPr-TAE in HEK293T cells drives base mutagenesis similar to that in plants
294 and yeast, but only in the absence of TARG1.

295 As different oligonucleotide templates revealed reduced templated repair with
296 increased base mutagenesis (**Fig. S17**), we repeated the editing assay without the
297 oligonucleotide template. Base mutagenesis at both modified thymines increased to 16%
298 (**Fig. 4d**), with conversion to either A or C at similar frequencies. Additionally, base
299 mutagenesis was reduced by 20-fold to 0.8% in the absence of DNA nicking, indicating the
300 importance of the nick (**Fig. 4d**). ADP-ribosylation in the absence of opposite-strand nicking
301 would also capture Cas9-independent off-targeting²³, suggesting that such off-targeting
302 would lead to limited editing despite use of a highly-active DarT2. Probing base mutagenesis
303 beyond this target site, we performed transient transfections without the oligonucleotide
304 template at 16 additional target sites in five genes containing one or more DarT2 recognition
305 motifs (**Figs. 4e and S18**). We observed measurable editing at all but two of these sites, with
306 editing frequencies reaching up to 39% (**Figs. 4e and S18**) and indel frequencies 6-110-fold
307 lower with ADPr-TAE than with Cas9 (**Fig. S19**). Similar trends were observed in
308 U2OS^{ΔTARG1} cells²⁸, with generally lower editing frequencies due to lower transfection
309 efficiencies (**Figs. S20-S21**).

310 The expanded set of target sites allowed us to explore unique features of base
311 mutagenesis. First, indel frequencies measured by next-generation sequencing or predicted
312 using the Rule Set 2 scoring method³⁰ at each target site with Cas9 correlated with base-
313 mutagenesis frequencies (Spearman correlation = 0.80 and 0.58 respectively) (**Fig. S22**).
314 The correlation indicates that efficient targeting and DNA cleavage offer a starting point to
315 identify efficient ADPr-TAE sites. Second, across these sites, editing principally occurred at
316 the modified thymine falling between positions 3 and 9 of sgRNA guide (**Fig. 4f**). For targets
317 with multiple DarT2 recognition motifs, co-occurring mutations were observed 1.1-5.1-fold
318 more frequently than expected if the motifs could be edited independently (**Fig. S23**). Finally,
319 we noticed distinct mutagenesis distributions that strongly depended on the DarT2
320 recognition motif (**Fig. 4g**). Specifically, 5'-TCTN-3' motifs were associated with similar

321 conversion frequencies to A and C. In contrast, 5'-TTTN-3' were associated with a strong
322 bias toward A, with secondary edits biased toward C (5'-TTTA-3') or equally split between C
323 and G (5'-TTTC-3'). In total, ADPr-TAE can drive base mutagenesis of thymines in human
324 cells paralleling that observed in yeast and plants, with TARG1 countering the effect of
325 DarT2.

326

327 **DISCUSSION**

328 In this work, we explored the impact of appending chemical moieties to target DNA as a
329 distinct yet broad approach for precision editing, what we call append editing. As a first
330 example, we used the bacterial toxin DarT2 to mediate ADP-ribosylation of thymine
331 (abbreviated as ADPr-TAE). When paired with opposite-strand nicking, ADPr-TAE
332 introduced precise edits through homologous recombination in tested bacteria, allowing the
333 creation of templated edits (**Fig. 5**). While this strategy also drove templated recombination
334 in yeast, the predominant outcome was mutagenesis of the ADP-ribosylated thymine. Base
335 mutagenesis was similarly observed in plants and mammalian cells, with a general bias
336 toward substitution to adenine or cytosine (**Fig. 5**). Although the exact underlying repair
337 pathways in eukaryotes remain to be identified (e.g., nucleotide-excision repair, translesion
338 synthesis), homologous recombination can at least be excluded. This divergence in repair
339 pathways contrasts with other genome-editing approaches that engage equivalent repair
340 pathways across organisms and result in similar types of edits, supporting append editing as
341 a distinct entry in the genome editing toolbox.

342 ADPr-TAE furthermore offers unique opportunities for genome editing in bacteria
343 (**Fig. 5**) exemplified by the broad range of generated sequence replacements, deletions and
344 insertions. This form of editing did not sacrifice colony counts compared to traditional dsDNA
345 cleavage³¹, offered broader edits without perturbing DNA repair compared to prime
346 editing^{32,33}, and omitted fixed scars compared to CRISPR-associated transposons³⁴. Given
347 these distinctions, ADPr-TAE is well suited for generating large chromosomal libraries and
348 multiplexed editing or multi-base editing in non-model bacteria³⁵.

349 In yeast, plants, and human cells, ADPr-TAE operates closest to BEs yet offers
350 distinct editing avenues (**Fig. 5**). BEs to date rely on base deaminases or glycosylases that
351 convert T (or A on the opposite strand) into C (adenosine deaminase)¹⁸, G (adenine
352 glycosylase)³⁶ or C/G (thymine glycosylase)³⁷⁻⁴⁰. In contrast, ADPr-TAE converts T to A or
353 A/C depending on the organism and sequence context. T-to-A editing is particularly unique
354 (**Fig. 5**), where ADPr-TAE could potentially revert 789 of the verified pathogenic SNVs
355 across 355 genes in the ClinVar database⁴¹ otherwise off-limits through existing thymine
356 base editors. While the current DarT2 recognition motif would capture a fraction of these
357 SNVs (i.e., 30 T-to-A; 447 T-to-C) (**Table S5**), relaxing the motif through ortholog mining or
358 protein engineering could access a greater set. A stringent motif can also be beneficial, such
359 as when reversing pathogenic mutations susceptible to bystander edits. In particular, ADPr-
360 TAE could create a single desired T-to-C edit in a stretch of three thymines (e.g., pathogenic
361 mutation in the third T of 5'-TTTG-3' (c.103C>T, c.4396C>T, c.4852C>T, c.5188C>T,
362 c.5623C>T, c.742C>T, c.748C>T) or 5'-TTTA-3' (c.1537C>T, c.3346C>T, c.3673C>T,
363 c.3826C>T, c.4603C>T, c.5473C>T, c.5599C>T)-3' in the *ATM* gene underlying Ataxia-
364 telangiectasia⁴²), while current adenine base editors would generate unwanted edits across
365 the thymines. TARG1 poses an immediate barrier to ADPr-TAE in human cells; however,
366 this barrier could be circumvented with peptide or chemical inhibitors⁴³, transient gene
367 silencing such as with RNA interference⁴⁴, or use of dominant-negative inhibitors such as
368 used against mismatch repair⁴⁵.

369 Beyond ADP-ribosylation of thymine with DarT2, a large number of base-modifying
370 enzymatic domains against any of the four nucleotides could expand append editing. For
371 instance, DarT1 toxins (related to DarT2) and eukaryotic toxins called pierisins (found in
372 cabbage moths) ADP-ribosylate the N2 position of guanine^{46,47}, with evidence of base
373 mutagenesis by pierisins in CHO cells⁴⁸. Additionally, bacteria and bacteriophages append
374 unique chemical moieties such as methylcarbamoyl⁴⁹, dPreQ₀⁵⁰, dADG⁵¹, glucosyl-5-
375 hydroxymethyl⁵², and 5-hydroxymethyl⁵³ to their DNA to block access by anti-phage
376 defenses⁵⁴. The associated enzymatic domains could be further engineered to alter the

377 modified nucleotide, the recognized motif, or the appended moiety as well as enhance
378 editing efficiencies. Interestingly, these examples consistently derive from host-
379 pathogen/parasite interactions that could serve as a plentiful source of such base-modifying
380 domains.

381 Finally, apart from genome editing, appending chemical moieties to DNA in a
382 targeted manner could facilitate the study of localized versus genome-wide DNA repair.
383 Evaluating the impact of DNA adducts is central to elucidating responsible modes of repair
384 potentially driving mutagenesis and carcinogenesis. To date, introducing such adducts at
385 specific chromosomal sites has proven extremely difficult and laborious⁵⁵. With append
386 editing, specific adducts could be studied in real time⁵⁶ or in conjunction with genome-wide
387 screen of repair pathways⁵⁷ thus uncovering the molecular basis of editing outcomes and
388 probable strategies to shape these outcomes.

389

390 **ACKNOWLEDGMENTS**

391 We thank Jimmy Jeske and Rachael Larose for technical support with plasmid cloning and
392 genomic DNA isolation and Ivan Ahel for providing the U2OS^{ΔTARG1} cell line²⁸. The zCas9i
393 MoClo-compatible CRISPR/Cas9 cloning kit with intronized Cas9 was a gift from Sylvestre
394 Marillonnet and Johannes Stuttmann (Addgene kit #1000000171)^{58,59}. Genome Analytics
395 Core Unit facility (GMAK) at HZI provided the high-throughput sequencing services. pX330-
396 U6-Chimeric_BB-CBh-hSpCas9 and pSpCas9(BB)-2A-GFP (PX458) were gifts from Feng
397 Zhang (Addgene plasmid # 42230⁶⁰; # 48138⁶¹).

398

399 **DATA AVAILABILITY**

400 The high-throughput sequencing data have been deposited in the National Center for
401 Biotechnology Information database (BioProject accession PRJNA1149814,
402 <https://dataview.ncbi.nlm.nih.gov/object/PRJNA1149814?reviewer=ldg27an527njpmagqvi9u>
403 [se8vj](#)). Source data for all figures are provided in **Table S3** and **Table S4**. There are no
404 restrictions on data availability.

405

406 **CODE AVAILABILITY**

407 R scripts used for the analysis of processed NGS data have been deposited on Github
408 (<https://gitfront.io/r/Christophe29/9bNjZzbgt6Vk/ADPr-TAE-analysis/>).

409

410 **FUNDING**

411 This work was supported by National Institutes of Health MIRA grant 1R35GM119561 (to
412 C.L.B.), European Research Council Consolidator grant 865973 (to C.L.B.), the North
413 Carolina Biotechnology Center grant 2022-TRG-6712 (to C.L.B.), a sponsored collaborative
414 research project with Syngenta (to C.L.B.), DAAD Forschungsstipendien Promotionen 20/21
415 (to D.G.), the fellowship program of the Vogel Stiftung Dr. Eckernkamp (to D.G.), the
416 International Graduate Program *RNAmed - Future Leaders in RNA-based Medicine* of the
417 Elite Network of Bavaria (to C.L.B.), National Science Foundation grants 1750006, 1444561
418 and 1940829 (to A.N.S. and J.M.A.), and an NSF predoctoral fellowship 2023356574 (to
419 K.V.).

420

421 **AUTHOR CONTRIBUTIONS**

422 **Conceptualization:** S.P.C. and C.L.B. **Methodology:** C.P., D.G., H.V.B., C.K., A.S.,
423 J.M.A, C.T., C.L.B. **In vitro assays:** C.K. **Bacterial assays:** C.P., H.V.B., I.K., A.M., T.A.,
424 A.D.R. **Yeast assays:** C.P., Y.W., T.N., I.S.A. **Plant assays:** K.V., C.Z. **Human cell assays:**
425 D.G., A.K. **Bioinformatic analysis:** D.G, C.T., H.V.B. **Writing manuscript:** C.P., D.G.,
426 H.V.B., C.K., C.L.B. **Reviewing and editing manuscript:** all authors, **Figure generation:**
427 C.P., D.G., H.V.B., C.K., C.L.B. **Supervision:** C.P., N.C., E.S., A.S., J.M.A, C.L.B. **Funding**
428 **acquisition:** A.S., J.M.A., C.L.B.

429

430 **CONFLICTS OF INTEREST**

431 C.L.B. is a co-founder and officer of Leopard Biosciences, co-founder and Scientific Advisor
432 to Locus Biosciences, and Scientific Advisor to Benson Hill. S.P.C. and K.M.P. are co-

433 founders and officers of Hoofprint Biome. C.P., D.G., H.V.B., S.P.C., K.V., C.Z., A.S., J.M.A.
434 and C.L.B. have filed related patent applications. The other authors have no conflicts of
435 interest to declare.

436

437 REFERENCES

- 438 1. Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable editing
439 of a target base in genomic DNA without double-stranded DNA cleavage. *Nature* **533**,
440 420–424 (2016).
- 441 2. Gu, S., Bodai, Z., Cowan, Q. T. & Komor, A. C. Base editors: Expanding the types of
442 DNA damage products harnessed for genome editing. *Gene and Genome Editing* **1**,
443 100005 (2021).
- 444 3. Rallapalli, K. L. & Komor, A. C. The Design and Application of DNA-Editing Enzymes as
445 Base Editors. *Annu. Rev. Biochem.* **92**, 43–79 (2023).
- 446 4. Amendola, M., Brusson, M. & Miccio, A. CRISPRthripsis: The risk of CRISPR/Cas9-
447 induced chromothripsis in gene therapy. *Stem Cells Transl. Med.* **11**, 1003–1009
448 (2022).
- 449 5. Abdullah *et al.* CRISPR base editing and prime editing: DSB and template-free editing
450 systems for bacteria and plants. *Synth Syst Biotechnol* **5**, 277–292 (2020).
- 451 6. Villiger, L. *et al.* CRISPR technologies for genome, epigenome and transcriptome
452 editing. *Nat. Rev. Mol. Cell Biol.* **25**, 464–487 (2024).
- 453 7. Mok, B. Y. *et al.* A bacterial cytidine deaminase toxin enables CRISPR-free
454 mitochondrial base editing. *Nature* **583**, 631–637 (2020).
- 455 8. Porto, E. M. & Komor, A. C. In the business of base editors: Evolution from bench to
456 bedside. *PLoS Biol.* **21**, e3002071 (2023).
- 457 9. Jiang, G. *et al.* Molecular Mechanism of the Cytosine CRISPR Base Editing Process
458 and the Roles of Translesion DNA Polymerases. *ACS Synth. Biol.* **10**, 3353–3358
459 (2021).
- 460 10. Carusillo, A. & Mussolino, C. DNA Damage: From Threat to Treatment. *Cells* **9**, (2020).

- 461 11. Wozniak, K. J. & Simmons, L. A. Bacterial DNA excision repair pathways. *Nat. Rev.*
462 *Microbiol.* **20**, 465–477 (2022).
- 463 12. Khatib, J. B., Nicolae, C. M. & Moldovan, G.-L. Role of translesion DNA synthesis in the
464 metabolism of replication-associated nascent strand gaps. *J. Mol. Biol.* **436**, 168275
465 (2024).
- 466 13. Jankevicius, G., Ariza, A., Ahel, M. & Ahel, I. The Toxin-Antitoxin System DarTG
467 Catalyzes Reversible ADP-Ribosylation of DNA. *Mol. Cell* **64**, 1109–1116 (2016).
- 468 14. LeRoux, M. *et al.* The DarTG toxin-antitoxin system provides phage defence by ADP-
469 ribosylating viral DNA. *Nat Microbiol* **7**, 1028–1040 (2022).
- 470 15. Schuller, M. *et al.* Molecular basis for DarT ADP-ribosylation of a DNA base. *Nature*
471 **596**, 597–602 (2021).
- 472 16. Deep, A. *et al.* Structural insights into DarT toxin neutralization by cognate DarG
473 antitoxin: ssDNA mimicry by DarG C-terminal domain keeps the DarT toxin inhibited.
474 *Structure* **31**, 780–789.e4 (2023).
- 475 17. Lawarée, E. *et al.* DNA ADP-Ribosylation Stalls Replication and Is Reversed by RecF-
476 Mediated Homologous Recombination and Nucleotide Excision Repair. *Cell Rep.* **30**,
477 1373–1384.e4 (2020).
- 478 18. Gaudelli, N. M. *et al.* Programmable base editing of A•T to G•C in genomic DNA without
479 DNA cleavage. *Nature* **551**, 464–471 (2017).
- 480 19. Zheng, K. *et al.* Highly efficient base editing in bacteria using a Cas9-cytidine
481 deaminase fusion. *Commun Biol* **1**, 32 (2018).
- 482 20. Chatterjee, P., Jakimo, N. & Jacobson, J. M. Minimal PAM specificity of a highly similar
483 SpCas9 ortholog. *Science Advances* (2018) doi:10.1126/sciadv.aau0766.
- 484 21. Vento, J. M., Crook, N. & Beisel, C. L. Barriers to genome editing with CRISPR in
485 bacteria. *J. Ind. Microbiol. Biotechnol.* **46**, 1327–1341 (2019).
- 486 22. Tang, W. & Liu, D. R. Rewritable multi-event analog recording in bacterial and
487 mammalian cells. *Science* **360**, (2018).
- 488 23. Doman, J. L., Raguram, A., Newby, G. A. & Liu, D. R. Evaluation and minimization of

- 489 Cas9-independent off-target DNA editing by cytosine base editors. *Nat. Biotechnol.* **38**,
490 620–628 (2020).
- 491 24. Jumper, J. *et al.* Highly accurate protein structure prediction with AlphaFold. *Nature* **596**,
492 583–589 (2021).
- 493 25. Gros Lambert, J., Prokhorova, E. & Ahel, I. ADP-ribosylation of DNA and RNA. *DNA*
494 *Repair* **105**, 103144 (2021).
- 495 26. Vanderwaeren, L., Dok, R., Voordeckers, K., Nuyts, S. & Verstrepen, K. J.
496 *Saccharomyces cerevisiae* as a Model System for Eukaryotic Cell Biology, from Cell
497 Cycle Control to DNA Damage Response. *Int. J. Mol. Sci.* **23**, (2022).
- 498 27. Hirohata, A. *et al.* CRISPR/Cas9-mediated homologous recombination in tobacco. *Plant*
499 *Cell Rep.* **38**, 463–473 (2019).
- 500 28. Tromans-Coia, C. *et al.* TARG1 protects against toxic DNA ADP-ribosylation. *Nucleic*
501 *Acids Res.* **49**, 10477–10492 (2021).
- 502 29. Huang, M. E. *et al.* C-to-G editing generates double-strand breaks causing deletion,
503 transversion and translocation. *Nat. Cell Biol.* **26**, 294–304 (2024).
- 504 30. Doench, J. G. *et al.* Optimized sgRNA design to maximize activity and minimize off-
505 target effects of CRISPR-Cas9. *Nat. Biotechnol.* **34**, 184–191 (2016).
- 506 31. Pyne, M. E., Moo-Young, M., Chung, D. A. & Chou, C. P. Coupling the CRISPR/Cas9
507 System with Lambda Red Recombineering Enables Simplified Chromosomal Gene
508 Replacement in *Escherichia coli*. *Appl. Environ. Microbiol.* **81**, 5103–5114 (2015).
- 509 32. Zhang, H. *et al.* BacPE: a versatile prime-editing platform in bacteria by inhibiting DNA
510 exonucleases. *Nat. Commun.* **15**, 825 (2024).
- 511 33. Tong, Y., Jørgensen, T. S., Whitford, C. M., Weber, T. & Lee, S. Y. A versatile genetic
512 engineering toolkit for *E. coli* based on CRISPR-prime editing. *Nat. Commun.* **12**, 5206
513 (2021).
- 514 34. Klompe, S. E., Vo, P. L. H., Halpin-Healy, T. S. & Sternberg, S. H. Transposon-encoded
515 CRISPR-Cas systems direct RNA-guided DNA integration. *Nature* **571**, 219–225 (2019).
- 516 35. Krink, N., Nikel, P. I. & Beisel, C. L. A Hitchhiker's guide to CRISPR editing tools in

- 517 bacteria : CRISPR can help unlock the bacterial world, but technical and regulatory
518 barriers persist. *EMBO Rep.* **25**, 1694–1699 (2024).
- 519 36. Tong, H. *et al.* Programmable A-to-Y base editing by fusing an adenine base editor with
520 an N-methylpurine DNA glycosylase. *Nat. Biotechnol.* **41**, 1080–1084 (2023).
- 521 37. He, Y. *et al.* Protein language models-assisted optimization of a uracil-N-glycosylase
522 variant enables programmable T-to-G and T-to-C base editing. *Mol. Cell* **84**, 1257–
523 1270.e6 (2024).
- 524 38. Ye, L. *et al.* Glycosylase-based base editors for efficient T-to-G and C-to-G editing in
525 mammalian cells. *Nat. Biotechnol.* (2024) doi:10.1038/s41587-023-02050-w.
- 526 39. Yi, Z. *et al.* Programmable DNA pyrimidine base editing via engineered uracil-DNA
527 glycosylase. *Nat. Commun.* **15**, 6397 (2024).
- 528 40. Tong, H. *et al.* Development of deaminase-free T-to-S base editor and C-to-G base
529 editor by engineered human uracil DNA glycosylase. *Nat. Commun.* **15**, 4897 (2024).
- 530 41. Landrum, M. J. *et al.* ClinVar: improving access to variant interpretations and supporting
531 evidence. *Nucleic Acids Res.* **46**, D1062–D1067 (2018).
- 532 42. Elitzur, S. *et al.* ATM germ line pathogenic variants affect outcomes in children with
533 ataxia-telangiectasia and hematological malignancies. *Blood* **144**, 1193–1205 (2024).
- 534 43. Wang, L. *et al.* Enhanced base editing by co-expression of free uracil DNA glycosylase
535 inhibitor. *Cell Res.* **27**, 1289–1292 (2017).
- 536 44. Shahryari, A. *et al.* Increasing Gene Editing Efficiency for CRISPR-Cas9 by Small RNAs
537 in Pluripotent Stem Cells. *CRISPR J* **4**, 491–501 (2021).
- 538 45. Chen, P. J. *et al.* Enhanced prime editing systems by manipulating cellular determinants
539 of editing outcomes. *Cell* **184**, 5635–5652.e29 (2021).
- 540 46. Takamura-Enya, T. *et al.* Mono(ADP-ribosyl)ation of 2'-deoxyguanosine residue in DNA
541 by an apoptosis-inducing protein, pierisin-1, from cabbage butterfly. *Proc. Natl. Acad.*
542 *Sci. U. S. A.* **98**, 12414–12419 (2001).
- 543 47. Schuller, M. *et al.* Molecular basis for the reversible ADP-ribosylation of guanosine
544 bases. *Mol. Cell* **83**, 2303–2315.e6 (2023).

- 545 48. Totsuka, Y. *et al.* Analysis of HPRT and supF mutations caused by pierisin-1, a guanine
546 specific ADP-ribosylating toxin derived from the cabbage butterfly. *Chem. Res. Toxicol.*
547 **16**, 945–952 (2003).
- 548 49. Karambelkar, S. *et al.* Emergence of a novel immune-evasion strategy from an
549 ancestral protein fold in bacteriophage Mu. *Nucleic Acids Res.* **48**, 5294–5305 (2020).
- 550 50. de Crécy-Lagard Valérie *et al.* Biosynthesis and function of 7-deazaguanine derivatives
551 in bacteria and phages. *Microbiol. Mol. Biol. Rev.* **88**, e00199–23 (2024).
- 552 51. Hutinet, G. *et al.* 7-Deazaguanine modifications protect phage DNA from host restriction
553 systems. *Nat. Commun.* **10**, 5442 (2019).
- 554 52. Vlot, M. *et al.* Bacteriophage DNA glucosylation impairs target DNA binding by type I
555 and II but not by type V CRISPR-Cas effector complexes. *Nucleic Acids Res.* **46**, 873–
556 885 (2018).
- 557 53. Wang, S. *et al.* Landscape of New Nuclease-Containing Antiphage Systems in
558 *Escherichia coli* and the Counterdefense Roles of Bacteriophage T4 Genome
559 Modifications. *J. Virol.* **97**, e0059923 (2023).
- 560 54. Weigele, P. & Raleigh, E. A. Biosynthesis and Function of Modified Bases in Bacteria
561 and Their Viruses. *Chem. Rev.* **116**, 12655–12687 (2016).
- 562 55. Pagès, V., Mazón, G., Naiman, K., Philippin, G. & Fuchs, R. P. Monitoring bypass of
563 single replication-blocking lesions by damage avoidance in the *Escherichia coli*
564 chromosome. *Nucleic Acids Res.* **40**, 9036–9043 (2012).
- 565 56. Liu, Y. *et al.* Very fast CRISPR on demand. *Science* **368**, 1265–1269 (2020).
- 566 57. Hussmann, J. A. *et al.* Mapping the genetic landscape of DNA double-strand break
567 repair. *Cell* **184**, 5653–5669.e25 (2021).
- 568 58. Grützner, R. *et al.* High-efficiency genome editing in plants mediated by a Cas9 gene
569 containing multiple introns. *Plant Commun* **2**, 100135 (2021).
- 570 59. Stuttmann, J. *et al.* Highly efficient multiplex editing: one-shot generation of 8× *Nicotiana*
571 *benthamiana* and 12× *Arabidopsis* mutants. *Plant J.* **106**, 8–22 (2021).
- 572 60. Cong, L. *et al.* Multiplex genome engineering using CRISPR/Cas systems. *Science* **339**,

- 573 819–823 (2013).
- 574 61. Ran, F. A. *et al.* Genome engineering using the CRISPR-Cas9 system. *Nat. Protoc.* **8**,
575 2281–2308 (2013).
- 576 62. Afroz, T., Biliouris, K., Boykin, K. E., Kaznessis, Y. & Beisel, C. L. Trade-offs in
577 engineering sugar utilization pathways for titratable control. *ACS Synth. Biol.* **4**, 141–149
578 (2015).
- 579 63. Datsenko, K. A. & Wanner, B. L. One-step inactivation of chromosomal genes in
580 *Escherichia coli* K-12 using PCR products. *Proc. Natl. Acad. Sci. U. S. A.* **97**, 6640–
581 6645 (2000).
- 582 64. Cutler, S. R., Ehrhardt, D. W., Griffiths, J. S. & Somerville, C. R. Random GFP::cDNA
583 fusions enable visualization of subcellular structures in cells of *Arabidopsis* at a high
584 frequency. *Proceedings of the National Academy of Sciences* **97**, 3718–3723 (2000).
- 585 65. Sarrion-Perdigones, A. *et al.* GoldenBraid 2.0: a comprehensive DNA assembly
586 framework for plant synthetic biology. *Plant Physiol.* **162**, 1618–1631 (2013).
- 587 66. Li, H. Minimap2: pairwise alignment for nucleotide sequences. *Bioinformatics* **34**, 3094–
588 3100 (2018).
- 589 67. Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**,
590 2078–2079 (2009).
- 591 68. R Core Team. R: A Language and Environment for Statistical Computing. Preprint at
592 <https://www.R-project.org/> (2024).
- 593 69. Zheng, Z. *et al.* Symphonizing pileup and full-alignment for deep learning-based long-
594 read variant calling. *Nat Comput Sci* **2**, 797–803 (2022).
- 595 70. Galaxy Community. The Galaxy platform for accessible, reproducible and collaborative
596 biomedical analyses: 2022 update. *Nucleic Acids Res.* **50**, W345–W351 (2022).
- 597 71. Danecek, P. *et al.* Twelve years of SAMtools and BCFtools. *Gigascience* **10**, (2021).
- 598 72. Daniel Gietz, R. & Woods, R. A. Transformation of yeast by lithium acetate/single-
599 stranded carrier DNA/polyethylene glycol method. in *Methods in Enzymology* (eds.
600 Guthrie, C. & Fink, G. R.) vol. 350 87–96 (Academic Press, 2002).

- 601 73. Katoh, K. & Standley, D. M. MAFFT multiple sequence alignment software version 7:
602 improvements in performance and usability. *Mol. Biol. Evol.* **30**, 772–780 (2013).
- 603 74. Richter, M. F. *et al.* Phage-assisted evolution of an adenine base editor with improved
604 Cas domain compatibility and activity. *Nat. Biotechnol.* **38**, 883–891 (2020).
- 605 75. Thuronyi, B. W. *et al.* Continuous evolution of base editors with expanded target
606 compatibility and improved activity. *Nat. Biotechnol.* **37**, 1070–1079 (2019).
- 607 76. Zhao, D. *et al.* Glycosylase base editors enable C-to-A and C-to-G base changes. *Nat.*
608 *Biotechnol.* **39**, 35–40 (2020).
- 609 77. Chen, L. *et al.* Adenine transversion editors enable precise, efficient A•T-to-C•G base
610 editing in mammalian cells and embryos. *Nat. Biotechnol.* **42**, 638–650 (2024).
- 611 78. Tong, H. *et al.* Programmable deaminase-free base editors for G-to-Y conversion by
612 engineered glycosylase. *Natl Sci Rev* **10**, nwad143 (2023).

613

614 **METHODS**

615 **Polymerase blocking assays**

616 Wildtype and inactivated (E170A) EPEC DarT2 proteins were expressed using the cell-free
617 myTXTL master mix (Arbor Biosciences). Linear DarT expression templates were amplified
618 from plasmids or ordered as synthetic gene fragments (Integrated DNA Technologies), and
619 contained a T7 promoter and T7 terminator to allow for gene expression (**Table S2**). Cell-
620 free expression was performed in 12 μ L reactions, comprising 9 μ L of myTXTL master mix, 4
621 nM of EPEC DarT2 template, 0.4 nM of a T7 RNA polymerase-encoding plasmid, and 4 μ M
622 of the RecBCD inhibitor GamS to prevent degradation of the linear DNA templates. The
623 reactions were incubated for 16 h at 29°C.

624 For ADP-ribosylation of ssDNA templates, the ADP-ribosylation assay was adapted
625 from prior work with slight alterations¹³. Briefly, 5 μ L of the TXTL-reaction mix were
626 incubated with 10 μ M of the ssDNA oligo, 50 μ M NAD⁺, 50 mM Tris-HCl pH 8, 150 mM NaCl,
627 10 mM EDTA and sterile nuclease free water to reach a final volume of 20 μ L, and incubated

628 for 30 min at 30°C. Afterwards, the oligos were separated from the mix using the Oligo clean
629 & concentrator kit (Zymo).

630 To assess whether DNA ADP-ribosylation blocks DNA polymerases *in vitro*, the
631 DarT-treated oligos were first annealed to the 5' 6-Fam-tagged primer CKo20 at a final
632 concentration of 10 µM in 1x NEBuffer 2 by heating the mixture to 94°C and gradually
633 cooling it to room temperature. Next, 2 µL of the annealed product were mixed with 0.5 U
634 Klenow Fragment (NEB), 33 µM dNTPs, and 1x NEBuffer 2 in a total volume of 12.5 µL, and
635 incubated for 15 min at 37°C. To stop the reaction, EDTA was added to a final concentration
636 of 10 mM and the samples were incubated at 75°C for 20 min.

637 To visualize the block of polymerisation, 4 µL of the polymerisation product was
638 mixed with 4 µL loading dye (containing 95% formamide, 0.03% SDS, 18 mM EDTA, 23 µM
639 xylene cyanol, and 19 µM bromophenol blue), and loaded onto a pre-heated denaturing
640 polyacrylamide gel (8 M urea, 20% PAA (19:1)). The gel was run at 250 V for 30 min and
641 visualized under UV light before and after staining with SYBR Gold (Thermo Fisher).

642

643 **Microbial strains, handling and growth conditions**

644 All bacterial and yeast strains used in this study are listed in **Table S2**. Unless
645 otherwise specified, *E. coli* TOP10 was used for plasmid cloning and propagation and was
646 grown at 37°C in LB liquid medium (10 g/L tryptone, 5 g/L yeast extract, 10 g/L NaCl)
647 shaking orbitally at 200 rpm, or on LB solid medium (15 g/L agar) at 37°C, containing
648 kanamycin (50 mg/L), carbenicillin (100 mg/L) or chloramphenicol (34 mg/L), when
649 appropriate. The *E. coli kanR** strain (CBS-4802) began as strain CB330 (*E. coli* MG1655
650 *P*_{J23110}-*araFGH* Δ *araBAD*), selected for uniform arabinose induction, to which two
651 chromosomal modifications were made. First, the Δ *lacZ* phenotype (W519*) was generated
652 by CBE-mediated deamination of 5'-ACC-3' to 5'-ATT-3' (POS 364749 & 364750 in
653 MG1655), resulting in a premature stop codon; this edit was not used in this work. Second, a
654 defective *kanR* expression construct (*kanR**) (see **Table S2** for an annotated sequence of
655 the genomic locus) containing a premature stop codon (Q177*) and DarT2 motif 5'-TTTC-3',

656 was inserted between genes *ybjM* and *grxA* (POS 890463 - 890480 in MG1655) by Red-
657 mediated recombination with Cas9 counterselection^{1,31,62}. The resulting *E. coli* MG1655
658 *kanR** strain was used for all assays related to the *kanR** gene. The *kanR** strain was further
659 used to generate $\Delta recA$, $\Delta recB$, $\Delta recF$, $\Delta recT$, $\Delta recJ$, $\Delta recO$, $\Delta xthA$, $\Delta mutS$ and $\Delta uvrA$
660 mutants by Red-mediated recombination⁶³. Briefly, transformants of the *E. coli kanR** strain
661 carrying pKD46 (encoding λ Red- γ , - β , -exo) were cultured in L-arabinose at 30°C until an
662 OD₆₀₀ of ~0.6, made electrocompetent as previously described⁶³, then transformed with a
663 linear dsDNA template containing 40 nt homology arms to mediate deletion of the target
664 gene. Next, pKD46 was cured from the bacteria by growing them at 37°C, after which the
665 bacteria were made electrocompetent and transformed with pCP20, then grown at 42°C to
666 simultaneously express FLP recombinase and eliminate pCP20. Colonies were then
667 screened for gene deletion by colony PCR and Sanger sequencing. For the substitution
668 assays targeting the *aaaD*, *punR*, *ygcQ* and *yheO* genes, the *E. coli* MG1655 strain was
669 used.

670 *Salmonella enterica* subsp. *enterica* serovar Typhimurium str. LT2 was used for all
671 ADPr-TAE assays in *Salmonella* and was regularly grown at 37°C in LB liquid medium
672 shaking orbitally at 200 rpm or on solid LB medium. Carbenicillin (100 mg/L) and
673 chloramphenicol (34 mg/L) were supplemented in the growth medium when necessary.

674 The *S. cerevisiae* BY4741 ($\Delta trp1$, $\Delta leu2$) strain was used for all yeast experiments.
675 Unless otherwise specified, *S. cerevisiae* was grown in non-selective liquid YPD medium (20
676 g/L peptone, 10 g/L yeast extract, and 2% (w/v) D(+)-glucose) or on solid non-selective YPD
677 medium (20 g/L agar). To select for transformants, *S. cerevisiae* cells were grown on solid
678 synthetic defined (SD) medium w/o tryptophan and leucine containing 6.9 g/L yeast nitrogen
679 base without amino acids (Formedium LTD, Cat. # CYN0402), 0.64 g/L complete
680 supplement mixture w/o tryptophan and leucine (Formedium LTD, Cat. # DCS0569), 20 g/L
681 D(+)-galactose (Sigma-Aldrich, Cat. # 15522-250G-R) and 20 g/L agar (Th. Geyer GmbH,
682 Cat. # 214510).

683

684 **Plasmid construction**

685 Annotated sequences of all plasmids used in this study are provided in **Table S2**.
686 Unless otherwise specified, general cloning methods such as KLD (KLD Enzyme Mix, Cat.
687 #M0554S) or Gibson assembly (NEBuilder® HiFi DNA Assembly Master Mix, Cat. #
688 E2621X) were used to assemble linear dsDNA fragments into plasmids. Linear dsDNA
689 fragments were amplified with Q5® High-Fidelity 2X Master Mix (NEB, Cat. # M0492L) and
690 purified using the NucleoSpin Gel and PCR Clean-up kit (Macherey-Nagel GmbH, Cat. #
691 740609.50). Plasmid sequences were verified either by full plasmid sequencing
692 (Plasmidsaurus Inc) or Sanger sequencing (Microsynth Seqlab GmbH).

693 To generate the append editors expressed in plants, the codon-optimized
694 DNA sequence for DarT^D was commercially synthesized (Twist Bioscience) with a
695 previously reported N7-NLS for expression in *N. benthamiana*⁶⁴, while the zCas9i (*Z. mays*
696 codon-optimized Cas9 coding sequence with 13 introns) was obtained from Addgene (Kit
697 #1000000171)⁵⁸. Both fragments were amplified using the iProof™ High-Fidelity PCR Kit
698 (Bio-Rad, Cat. #1725331). The dDarT, nzCas9i and dzCas9i variants were generated using
699 inverse PCR. Three gRNAs targeting the phytoene desaturase 1 gene (*PDS1*) (**Table S2**)
700 were cloned by annealing complementary oligos into an AtU6 gRNA cassette. Gene
701 fragments were assembled using the GoldenBraid cloning strategy⁶⁵.

702

703 ***kanR** reversion**

704 To assess ADPr-TAE in *E. coli*, an overnight culture of strain CBS-4802 was back-
705 diluted 100-fold, grown to ABS₆₀₀ of 0.6-0.8, then rendered electrocompetent in 10%
706 glycerol. For transformation, 40 µL of electrocompetent cells were mixed with the relevant
707 plasmid(s) and transferred to an ice cold 1-mm electroporation cuvette (Bio-Rad
708 Laboratories, Cat. 1652089). Cells were electroporated using the Gene Pulser Xcell
709 Microbial System (Bio-Rad Laboratories; Cat # 1652662) and the following settings: 1.8 kV,
710 25 µF, 200 Ω. Next, cells were supplemented with 500 µL of SOC medium and recovered for
711 1 h at 37°C, shaking orbitally at 200 rpm. Cells were collected by centrifugation at 3000x g,

712 the supernatant was decanted and cells were resuspended in 2 mL induction medium (LB,
713 L-arabinose (2% w/v), carbenicillin (100 mg/L) and chloramphenicol (34 mg/L)) and
714 incubated at 37°C for 16 h, shaking orbitally at 200 rpm. Afterwards, cell cultures were
715 serially diluted in five ten-fold steps in LB, from which 5 µL of each dilution was spotted on
716 LB solid medium containing either carbenicillin and chloramphenicol to select for
717 transformed cells, or carbenicillin, chloramphenicol, and kanamycin to select for transformed
718 and edited cells. The spotted LB solid medium was then incubated for 16 h at 37°C followed
719 by counting colonies.

720

721 **Replacement, deletion, and insertion assays in *E. coli***

722 For the *E. coli* replacement, deletion, and insertion assays at the *kanR** locus and the
723 substitution assays at the *aaaD*, *punR*, *ygcQ*, and *yheO* genes, an identical transformation
724 and selection protocol was used as described above. However, after the 16 h incubation in
725 the induction medium, 100 µL of the cell culture was plated on LB solid medium containing
726 carbenicillin and chloramphenicol to obtain single colonies. Single colonies were
727 resuspended in Q5® High-Fidelity 2X Master Mix (NEB, Cat. # M0492L) containing the
728 appropriate primers and subjected to PCR amplification following the instructions of the
729 manufacturer and extending the initial heating step of 98°C to 5 mins to mediate cell lysis
730 and release of genomic DNA. Amplicons were purified and sequenced through Sanger
731 sequencing (Microsynth Seqlab GmbH).

732

733 **Growth-based toxicity assay in *E. coli***

734 The growth-based toxicity assay began by rendering strain CBS-5301
735 electrocompetent. Next, 9 fmol of plasmid CBS-4808 was transformed into strain CBS-5301
736 using the electroporation conditions described above. Transformants were recovered in 500
737 µL of SOC medium for 1 h at 37°C, shaking orbitally at 200 rpm, then plated on LB solid
738 medium supplemented with carbenicillin and incubated for 16 h at 37°C. Next, a single
739 colony was inoculated into 2 mL LB medium containing carbenicillin, grown until an OD₆₀₀ of

740 0.6, then made electrocompetent following the protocols described above. A second round
741 of transformation was performed, using one of nine different editor plasmids (CBS-6738/
742 6739/-6741/-6742/-6743/-6744/-6745/4781/-4800), following the electroporation protocol
743 described above. Transformed cells were allowed to recover in 500 μ L SOC medium for 1 h
744 at 37°C shaking orbitally at 200 rpm, plated on LB solid medium supplemented with
745 carbenicillin, chloramphenicol and glucose (20 mM), and incubated for 16 h at 37°C. Three
746 individual colonies from each of the nine resulting strains (**Table S2**) were then used to
747 inoculate a 96 deep-well plate (Greiner Bio-One Cat. # 780271), containing 400 μ L of LB
748 medium supplemented with carbenicillin, chloramphenicol and glucose (20 mM) and covered
749 with an adhesive gas-permeable membrane (Thermo Scientific, Cat. # 241205). After
750 incubating the deep-well plate for 16 h at 37°C, the cell cultures were adjusted to an OD₆₀₀
751 equal to 0.1 using LB supplemented with carbenicillin, chloramphenicol, and L-arabinose
752 (0.2% w/v) in a new 96-well plate, reaching a final volume of 200 μ L. The 96-well plate was
753 then measured every 3 minutes over 12 h at 37°C for absorbance at 600 nm on a BioTek
754 Synergy Neo2 plate reader, shaking at 500 rpm.

755

756 **Non-selective editing at *kanR****

757 Transformations were performed as described above, however after the 16 h incubation in
758 induction medium, the cultures were centrifuged, the medium was discarded, and genomic
759 DNA was isolated using Wizard Genomic DNA Purification Kit (Promega, Cat. # A1120). The
760 *kanR* site was then amplified through PCR using the primer pair HBo-314 and HBo-315 and
761 the Q5® High-Fidelity 2X Master Mix (NEB, Cat. # M0492L) for 25 cycles. Resulting
762 amplicons were sequenced with Nanopore sequencing (Eurofins Genomics Germany
763 GmbH). For data analysis, FASTQ sequencing data files were aligned to a FASTA file of the
764 unedited amplicon using MiniMap2 with option “map-ont”⁶⁶. Samtools was used to convert
765 the sequence alignment/map (SAM) files into binary alignment/map (BAM) files, while
766 concurrently sorting and indexing⁶⁷. All further analysis was performed using R, after calling
767 libraries tidyverse and GenomicAlignments⁶⁸. A function was defined to take BAM files as an

768 argument, then extract all alleles aligned to the 8 nucleotide region of the templated edit as a
769 list of characters. This function was applied to all BAM files to generate lists of alleles, which
770 were tallied and compiled into a single data frame in long table format. Next, alleles were
771 defined as unedited, edited, or ambiguous, and the fraction of each observation was
772 computed. Samples were then grouped by editor and repair plasmids, after which the mean
773 and standard deviation were computed, then used to generate the bar plot. Further analysis
774 was undertaken to search for base mutations at the ADPr site. The list of alleles in the initial
775 data frame was filtered to retain only records containing a T-to-V mutation at the ADPr target
776 position, but otherwise match the reference allele. Records were grouped by sample, SNVs
777 were tallied, after which each was divided by the total number of observed alleles and
778 multiplied by 100, to obtain the percent of base mutations amongst all sequencing reads.

779

780 **Whole genome off-target assay in *E. coli***

781 For identifying whole genome off-target mutations, strain CBS-4802 was grown from a single
782 colony in LB medium and made electrocompetent as described above. Electrocompetent
783 CBS-4802 was then co-transformed with equimolar amounts (9 fmol) of CBS-6746 and one
784 of several editor plasmids (CBS-3130/-6738/-6740). Transformants were recovered in 500
785 μ L SOC for 1 h at 37°C shaking orbitally at 200 rpm, after which the growth medium was
786 replaced with 2 mL of LB, supplemented with carbenicillin, chloramphenicol, and L-arabinose
787 (0.2%), followed by incubation at 37°C for 16 h shaking orbitally at 200 rpm. Next, the
788 cultures were streaked onto LB solid medium supplemented with carbenicillin and
789 chloramphenicol and incubated for 16 h at 37°C in order to obtain individual colonies. Three
790 colonies from each condition were in 2 mL of LB medium supplemented with carbenicillin
791 and chloramphenicol, and cultured for 16 h at 37°C.

792 After incubation, cultures were centrifuged and the cell pellets were subjected to
793 genomic DNA isolation using the Wizard Genomic DNA Purification Kit (Promega, Cat. #
794 A1120). Isolated genomic DNA was fully sequenced using Nanopore sequencing
795 (Plasmidsaurus Inc). For data analysis, FASTQ sequencing data files were aligned to a

796 FASTA file of *E. coli* MG1655 (GenBank: U00096.3), using Minimap2, with the “map-ont”
797 option⁶⁶. Samtools was used to convert the sequence alignment/map (SAM) files into binary
798 alignment/map (BAM) files, while concurrently sorting and indexing⁶⁷. Clair3 was run on the
799 GalaxyEU server, to call variants^{69,70}. Bcftools was used to query the variant call format
800 (VCF) files for POS, REF, ALT, DP, and AF fields, and export the results into a comma-
801 separated values (CSV) file⁷¹. The sequencing depth at all positions in all BAM files was
802 calculated by Samtools, and exported as a CSV file. All further analysis was performed in R
803 after loading library tidyverse⁶⁸. CSV files were loaded into a long format dataframe. This
804 dataframe was then filtered with the following steps. 1) SNVs were retained, by filtering for
805 records that contain only a single character in the REF and ALT fields. 2) SNVs already
806 present in the parent strain were eliminated, by filtering for records containing POS field
807 values not found in parent strain POS field values. 3) SNVs mapped to regions known to
808 have been modified during the creation of strain CBS-4802 were eliminated, by filtering for
809 records with POS field values not present in said regions. 4) Records were filtered for AF
810 field values greater than or equal to 0.25. 5) SNVs observed at a sequencing depth greater
811 than or equal to the lowest quartile of all BAM files ($Q1 \geq 34$) were retained. 6) All SNVs
812 were re-coded to C>D and T>V, tallied, then used to generate a heatmap.

813

814 **Editing assays in *S. enterica***

815 Electrocompetent *S. enterica* cells were transformed with 9 fmol of plasmid CBS-4800 and
816 recovered in 500 μ L SOC medium following an identical protocol as the one described
817 above for *E. coli*. After recovery, the cells were collected through centrifugation at 3,000x g,
818 the supernatant was decanted, and the cell pellet was resuspended in 100 μ L of LB medium.
819 The cell suspension was plated on LB solid medium containing chloramphenicol (34 mg/L)
820 and incubated at 37°C for 16 h. After incubation, a single colony was selected and used to
821 create electrocompetent *S. enterica* cells harboring plasmid CBS-4800, following the
822 protocol described above. Then, 22 fmol of the plasmids containing the repair template and
823 the targeting (T) sgRNA (**Table S2**) were transformed in triplicate through electroporation

824 into *S. enterica* cells harboring plasmid CBS-4800. The cells were recovered in 500 μ L SOC
825 medium, collected through centrifugation at 3,000x g, the supernatant was decanted, and
826 the cell pellet was resuspended in 2 mL of induction medium (LB, 2% (w/v) L-arabinose, 100
827 mg/L carbenicillin and 34 mg/L chloramphenicol) and grown at 37°C for 16 h, shaking
828 orbitally at 200 rpm. 100 μ L of the cell culture was plated on LB solid medium containing
829 carbenicillin and chloramphenicol to obtain single colonies. Colonies were resuspended in
830 Q5® High-Fidelity 2X Master Mix (NEB, Cat. # M0492L) containing the appropriate primers
831 and subjected to PCR amplification following the instructions of the manufacturer and adding
832 an initial heating step of 98°C for 5 min to mediate cell lysis and release of genomic DNA.
833 Amplicons were then purified using the NucleoSpin Gel and PCR Clean-up kit (Macherey-
834 Nagel GmbH, Cat. # 740609.50) and sequenced through Sanger sequencing (Microsynth
835 Seqlab GmbH).

836

837 **Templated editing assays in *S. cerevisiae***

838 *S. cerevisiae* BY4741 ($\Delta trp1$, $\Delta leu2$) cells were co-transformed with two plasmids, one
839 bearing either of the editor variants (DarT^{D_{LAA}}-nCas9 or dDarT-nCas9) and the other bearing
840 a 6 bp substitution template flanked by 294-bp (upstream) and 232-bp (downstream)
841 homology arms along with either an *FCY1* targeting (T) sgRNA or a non-targeting (NT)
842 sgRNA (**Table S2**), following the lithium acetate method as previously described⁷².

843 Briefly, single *S. cerevisiae* colonies were inoculated into 2 mL liquid YPD medium
844 (20 g/L peptone, 10 g/L yeast extract, 2% (w/v) D(+)-glucose) and grown for 16 h at 30°C,
845 shaking at 200 rpm on a rotary shaker. The cells were diluted to an OD₆₀₀ equal to 0.5 in 50
846 mL of YPD medium and cultured again at 30°C, shaking at 200 rpm, until the cells reached
847 an OD₆₀₀ equal to 2. The cells were then harvested by centrifugation at 3,000x g for 5 min,
848 the supernatant was decanted and the pellet was resuspended in 25 mL of sterile water. The
849 centrifugation and resuspension step was repeated followed by another centrifugation at
850 3,000x g for 5 min and resuspension in 1 mL of sterile water. The cell suspension was then
851 centrifuged for 30 s at 13,000x g, the supernatant was discarded and the pellet was

852 resuspended in 1 mL of sterile water. 100- μ L aliquots were distributed in 1.5 mL sterile
853 Eppendorf tubes, and the cells were collected by centrifugation at 13,000x g for 30 s. The
854 supernatant was decanted and the cell pellet was resuspended with 336 μ L of
855 transformation mix (240 μ L of PEG 3350, 36 μ L of 1 M LiAc, 50 μ L of 2 mg/mL single-
856 stranded carrier DNA), plasmid DNA (500 ng of each plasmid) and sterile water to reach a
857 final volume of 360 μ L. The suspension was incubated at 42°C for 40 min, after which it was
858 centrifuged at 13,000x g for 30 s. The supernatant was decanted, the cell pellet was
859 resuspended in 1 mL of YPD and the cell suspension was incubated for 3 h at 30°C. Cells
860 were collected by centrifugation at 13,000x g for 30 s and washed twice with 1 mL of SD
861 medium to remove any residual YPD medium. Finally, the cell pellet was resuspended with
862 100 μ L of SD medium, plated on solid SD medium without tryptophan and leucine and
863 containing D-galactose, and incubated at 30°C for 3 days or until colonies were visible.

864 Resulting colonies were collected with a sterile 10 μ L pipette tip and resuspended in
865 10 μ L sterile 0.02 M NaOH, boiled at 99°C for 10 min and centrifuged for 10 s at maximum
866 speed in a microcentrifuge. 1 μ L of the supernatant was used as template for PCR using the
867 Q5® High-Fidelity 2X Master Mix (NEB, Cat. # M0492L) and the primer pair prCP222-
868 prCP223 to amplify *FCY1* (**Table S2**). The resulting PCR product was purified using the
869 NucleoSpin Gel and PCR Clean-up kit (Macherey-Nagel GmbH, Cat. # 740609.50), following
870 the manufacturer's instructions. The final product was sequenced through Sanger
871 sequencing (Microsynth Seqlab GmbH). Sequence alignment was performed using the
872 online MAFFT algorithm⁷³.

873

874 **Base mutation assays in *S. cerevisiae***

875 *S. cerevisiae* BY4741 ($\Delta trp1$, $\Delta leu2$) cells were co-transformed with two plasmids, one
876 bearing either of the editor variants (DarT^{D_{LAA}}-nCas9 or dDarT-nCas9) and the other bearing
877 either of the targeting (T) sgRNAs for *FCY1*, *ALP1* or *JSN1*, or a non-targeting (NT) sgRNA
878 (**Table S2**), following identical procedures as described above. Resulting colonies were
879 screened through colony PCR as described above, and the primer pairs prCP222-prCP223,

880 prCP445-prCP446 and prCP441-prCP442 were used to amplify *FCY1*, *ALP1* and *JSN1*,
881 respectively (**Table S2**). The resulting PCR products were sequenced through Sanger
882 sequencing, and sequence alignment was performed using the MAFFT algorithm⁷³.

883

884 **Base mutation assays in *N. benthamiana***

885 *N. benthamiana* seeds were germinated in soil and transplanted at one-week-old stage to 24
886 cell nursery flats, one plant per cell, and grown at 23°C under a 16-h-light and 8-h-dark cycle
887 in Sungro horticulture professional grow mix mixed 1:1 with Jolly gardener Pro-line C/B
888 growing mix (Sungro).

889 Plasmids were used to electroporate *Agrobacterium tumefaciens* strain GV3101
890 using Bio-Rad GenePulser electroporator with the following conditions: 1.8 kV, 100 Ω, and
891 25 μFD. Single colonies were inoculated in LB medium containing spectinomycin (100
892 μg/mL), rifampicin (50 μg/mL), and gentamicin (50 μg/mL) for 16 h at 28°C with orbital
893 shaking at 200 rpm. Cultures were then centrifuged and resuspended in infiltration medium
894 (10 mM MgCl₂ and 100 μM Acetosyringone) to reach an OD₆₀₀ of ~0.1. Following, the
895 resuspended cultures were combined in a 1:1 ratio with an *A. tumefaciens* strain containing
896 *p19* (a suppressor of gene silencing) and were infiltrated into the leaves of four-week-old
897 plants using a 1-mL needleless syringe. The infiltrated plants were then recovered overnight
898 in the dark and grown for 7 days using conditions mentioned above.

899

900 **Next-Generation Sequencing in *N. benthamiana***

901 Leaf tissues were harvested 7 days post-infiltration using a standard hole-punch and
902 collected in 1.5 mL tubes containing ~100 μL of 1 mm glass beads. Disks from four leaves
903 (one disk per leaf) were pooled to create each biological replicate. The samples were frozen
904 at -80°C for 24 h, after which the tissue was ground using a Vivadent shaker for 5 s followed
905 by resuspension in CTAB buffer (1.4 M NaCl, 20 mM EDTA, pH 8, 100 mM Tris-HCl, pH 8,
906 3% CTAB (cetyltrimethylammonium bromide)). Cellular DNA was then extracted using
907 chloroform and isopropyl alcohol followed by a 70% ethanol wash.

908 The targeted region was amplified with optimized primers and PCR conditions, using
909 iProof™ High-Fidelity PCR Kit (Bio-Rad, Cat. #1725331). The products were purified using 4
910 μ L of ExoSAP-IT™ PCR Product Cleanup Reagent (Applied Biosystems, Cat.# A55242) at
911 37°C for 15 min followed by inactivation at 80°C for 15 min. A second amplification was
912 performed with iProof polymerases to introduce unique Illumina Barcodes and libraries were
913 purified using QIAquick Gel Extraction Kit (Qiagen).

914 The concentration for each library was measured using Qubit fluorometer (Invitrogen)
915 and equimolar amounts were pooled alongwith 120 pM phiX control library corresponding to
916 8% of the final volume. 20 μ L of the pooled library was loaded into the iSeq 100 (Illumina)
917 and the run was performed in accordance with iSeq 100 Sequencing System Guide.
918 Sequencing data analysis was performed as mentioned for mammalian cells.

919

920 **Mammalian cell cultures and transfection**

921 HEK293T cells were purchased from ATCC (CRL 11268) and U2OS ^{Δ TARG1} cell lines
922 were a gift from the Ahel lab. Unless otherwise mentioned, all cell lines were maintained
923 using Dulbecco's modified Eagle's medium (Life Technologies) supplemented with 10% (v/v)
924 fetal bovine serum (Corning and BANF Biotrend), 1x penicillin streptomycin (Life
925 Technologies) and 2 mM L-glutamine. The cultures were incubated in humidified incubators
926 at 37°C with 5% CO₂.

927 For generating HEK293T ^{Δ TARG1} cell line, cells were transfected with plasmids
928 containing WT-SpCas9 and TARG1 sgRNA²⁸ (**Table S2**) using Lipofectamine 3000™
929 (Invitrogen, Cat.# L3000008) according to the manufacturer's instructions. 48 h post-
930 transfection, cells were diluted and seeded in 96-well plates at a density of 3 cells/well.
931 Colonies were observed after 7 days and wells with single colonies were selected. Selected
932 clones were tested for TARG1 site disruption through Sanger sequencing followed by
933 Western Blotting (**Fig. S15.**) with anti-TARG1 antibody (Fisher Scientific, Cat.# 25249-1-
934 AP)²⁸ and anti-beta-actin antibody (Life technologies, Cat.# MA5-15739-HRP) as the
935 housekeeping control.

936 For templated editing assays in HEK293T (WT and $\Delta TARG1$) cell line, 65,000
937 cells/well were seeded onto tissue culture treated 24-well plates (Corning) and incubated at
938 37°C with 5% CO₂ under humidified conditions. 24 h later, 50 fmol of each plasmid was co-
939 transfected with 750 fmol of ssODN repair templates using 1.12 μ L of lipofectamine 3000™
940 reagent and 1 μ L of P3000. For base mutagenesis assays, 500 ng of each plasmid was
941 transfected, following the same conditions as mentioned above. The medium was refreshed
942 24 h post transfection and the cultures were harvested 72 h post transfection.

943 For base mutagenesis assays in the U2OS ^{$\Delta TARG1$} cell line, 1.3×10^5 cells were
944 seeded and 1 μ g of plasmid DNA, 1.5 μ L of lipofectamine 3000™ reagent, and 2 μ L of
945 P3000 were used for transfection. Media change and sample harvest were performed similar
946 to HEK293T cells.

947

948 **Next-generation sequencing for mammalian cells**

949 Genomic DNA was isolated from harvested cells using PureLink™ Genomic DNA
950 Mini Kit (Life Technologies, Cat. # K182002). Specific primers were used to amplify the
951 targeted region using Q5® High-Fidelity 2X Master Mix (NEB, Cat. # M0492L) through 27
952 cycles. The PCR product was purified using NucleoSpin Gel and PCR Clean-up Kit
953 (Macherey-Nagel, Cat. #740609) and was used as a template in KAPA HiFi HotStart
954 ReadyMix (Roche Diagnostics, Cat. # KK2602) to introduce Illumina adapter sequences
955 within 15 PCR cycles. The KAPA-PCR products were cleaned using Agencourt® AMPure®
956 XP magnetic beads (Beckman Coulter, Cat. # A63881) and 200 ng of this product was used
957 as template for a second PCR with KAPA Ready Mix to introduce Illumina Barcodes through
958 10 PCR cycles followed by cleanup using magnetic beads as mentioned before. PCR
959 products were screened at each step for correct fragment length using agarose gel
960 electrophoresis. The libraries were pooled in equimolar amounts and at least one million
961 reads were generated for each sample using NovaSeq™ 6000 and the demultiplexed data
962 was analyzed by CRISPResso2. Default parameters were used to perform the analysis
963 except when quantifying indel and HDR frequencies for templated editing, in which case a

964 plot_window_size = 30 was used. Allele_frequency_table_around_sgRNA.txt files
965 generated by CRISPResso2 were used within R-scripts
966 (<https://gitfront.io/r/Christophe29/9bNjZzbgt6Vk/ADPr-TAE-analysis/>) to further quantify Base
967 mutation frequencies as the total percentage of reads containing a nucleotide different from
968 the reference read.

969

970 **Statistical analyses**

971 For assays involving *kanR* reversion on solid medium (**Fig. 1g, 2b**), unpaired, two-
972 tailed, Welch's t-tests were performed on log-normal data. Figure error bars display standard
973 deviation. For the non-selective editing experiment (**Fig. S3**), a one-way ANOVA was
974 performed to test for the effect of editor-sgRNA combinations on the percent of reads
975 showing a SNV at the target thymidine. For the assay involving deletion strains in *E. coli*
976 (**Fig. 2e**), unpaired, one-tailed, Welch's t-tests were performed on log-normal data. Figure
977 error bars display standard deviation. For short-read NGS data (**Fig. 3f, 3g, 4c, 4d, 4e, 4g**),
978 unpaired, two-tailed, Welch's t-tests were performed. Figure error bars display standard error
979 of the mean. For the editing window experiment (**Fig. 4f**) median and quartiles of each
980 group are displayed. Related p-value calculations can be found in **Table S3** and **Table S4**.

FIGURES and LEGENDS

Fig. 1: Targeted DNA ADP-ribosylation drives template-mediated homologous recombination in *E. coli*. **a**, Role of the bacterial DarT2 toxin in anti-phage immunity. **b**, Conceptualized impact and resolution of DNA ADP-ribosylation on DNA replication in *E. coli*. Based on ref. ¹⁷. **c**, Experimental setup for the *in vitro* polymerase-blocking assay. EPEC DarT2 recognizes the 5'-TCTC-3' but not the 5'-ACTC-3' motif. dDarT2: DarT2 with catalytically inactivating E170A mutation. **d**, Impact of DNA ADP-ribosylation by DarT2 on DNA polymerase extension *in vitro*. Gel images are representative of duplicate independent experiments. See Figure S1 for additional controls. **e**, Configuration of the append editor utilizing DarT2. The editor combines ScCas9 mutated to nick the target DNA strand and a fused DarT2 that ADP-ribosylates the non-target DNA strand displaced as part of R-loop formation. This combination is predicted to drive homologous recombination with a provided repair template. **f**, Experimental setup for reverting a prematurely terminated kanamycin resistance gene (*kanR**) in *E. coli*. The chromosomally integrated gene contains a premature stop codon that is reverted as part of homologous recombination, thus conferring kanamycin resistance. RT: DNA repair template. **g**, Impact of programmable DNA ADP-ribosylation on cell viability and kanamycin-resistance frequency. Bars and error bars represent the geometric mean and geometric s.d. of three independent experiments started from separate transformations. Dots represent individual measurements. CFU: colony-forming units. T sgRNA: sgRNA with a guide targeting the intended site. NT sgRNA: sgRNA with a non-targeting guide. Below: cartoons designate whether a given DNA strand is unaltered, nicked or ADP-ribosylated. **h**, Amplicon sequencing of the *kanR** target site from batch cultures. Bars and error bars represent the mean and s.d. of three independent experiments starting from separate transformations. Dots represent individual measurements. **i**, Genome-wide profiling of off-target edits. The indicated editor was expressed with a non-targeting sgRNA and in the absence of an RT. See Table S1 for more information on the identified edits. Whole-genome sequencing was performed on genomic DNA extracted from cultures

beginning with an individual colony. Both strands are considered for a given edit (e.g., T > A and A > T are combined).

Fig. 2: Attenuating DarT2 alleviates cytotoxicity while mediating efficient and flexible gene editing in *E. coli*. **a**, Predicted structure of EPEC DarT2. Tested substitutions are in blue. **b**, Impact of tested substitutions on cell viability and kanamycin-resistance frequency. See Figure 1f for the experimental setup. **c**, Experimental setup for assessing growth defects caused by editor expression in a $\Delta recA$ -deletion strain of *E. coli*. **d**, Impact of expressing an append editor with the indicated DarT2 mutant with a non-targeting sgRNA in the $\Delta recA$ -deletion strain of *E. coli*. Endpoint optical density (OD) measurements were taken after 12 h of culturing. See Figure S5 for growth curves. Bars and error bars in b and e represent mean \pm geometric s.d. of three independent experiments started from separate transformations. Dots represent individual measurements. **e**, Impact of deleting DNA repair genes on cell viability and kanamycin-resistance frequency. Bars and error bars in b and e represent geometric mean \pm geometric s.d. of three independent experiments starting from separate transformations. Dots represent individual measurements. **f**, Introducing sequence replacements with ADPr-TA editing. **g**, Introducing deletions with ADPr-TA editing. **h**, Introducing insertions with ADPr-TA editing. For f-h, Left: size and location of substitutions (red bar), deletions (dashed box), or insertions (green bar). Numbers (e.g., +5/-12) indicate the edited region in relation to the ADP-ribosylated thymine. Right: fraction of screened colonies containing the intended edit. Each bar represents one of two biological replicates starting from separate transformations, screening at least 8 colonies per biological replicate. See Figure S7 for examples of Sanger sequencing chromatograms indicating edited, mixed, and unedited colonies.


Fig. 3: Programmable DNA ADP-ribosylation primarily drives base mutagenesis in yeast and plants. **a**, Experimental setup for introducing a six-base replacement with two adjacent premature stop codons in the *FCY1* gene of *S. cerevisiae*. **b**, Impact of ADPr-TAE









on templated recombination in the presence of a RT. Bars and error bars represent the mean and s.d. of three independent experiments started from separate transformations. Dots represent individual measurements. **c**, Impact of ADPr-TAE on mutagenesis of the ADP-ribosylated thymine in the presence or absence of a RT. **d**, Frequency of base mutations across the sgRNA target. Each black bar specifies DarT2 recognition motifs, while the red base specifies the ADP-ribosylated base within the motif. See Figure S10-S11 for representative Sanger sequencing chromatograms. For c-d, bars and error bars represent the mean and s.d. of three independent experiments started from separate transformations. **e**, Experimental setup for assessing ADPr-TAE without a repair template in *N. benthamiana*. **f**, Frequency of base mutagenesis of the ADP-ribosylated thymine in the sgRNA 1 target in the *PDS1* gene compared to the non-targeting control. **g**, Frequency of base mutations across the DNA target for sgRNA1-3 compared to the non-targeting control. See Figure S13 for the location of base mutations under targeting and non-targeting conditions. For f-g, bars and error bars represent the mean and SEM of three independent experiments started from separate transformations.


Fig. 4: Programmable DNA ADP-ribosylation preferentially drives base mutagenesis in human cells lacking TARG1. **a**, Reversion of ADP-ribosylation of ssDNA in human cells by the TARG1 protein. **b**, Experimental setup for introducing edits in the *EMX1* gene in HEK293T cells using an oligonucleotide repair template (RT). **c**, Extent of templated recombination (top), indel formation (middle) or base mutagenesis (bottom) using *EMX1* sgRNA1 in HEK293T cells with TARG1 intact (WT) or disrupted (Δ TARG1). Bars and error bars represent the mean and SEM of three independent transient transfections without selection or sorting. **d**, Frequency of base substitutions across the sgRNA target in the absence of the oligonucleotide RT. Results are shown with DNA nicking by Cas9 intact (top) or disabled (bottom). **e**, Extent of base mutagenesis of the ADP-ribosylated thymine across 17 target sites in five genes. For d and e, bars and error bars represent the mean and SEM of three independent transient transfections without selection or sorting. **f**, Extent of base


mutagenesis based on the relative location of the ADP-ribosylated thymine. Cumulative thymine base editing across 21 sgRNA targets, within 37 5'-TYTN-3' motifs at positions 3 - 14 (Position 1 being at the PAM-distal end). Solid black lines represent the median, gray lines represent the quartiles. Each dot represents the mean of three independent transient transfections without selection or sorting for a given sgRNA. **g**, Relationship between the outcome of base mutagenesis and the DarT2 recognition sequence. Distributions were calculated for base mutations occurring at 33 DarT2 recognition motifs across 21 sgRNAs. Bars and error bars represent the mean and SEM of fraction of total values.

Fig. 5: Programmable ADP-ribosylation of thymine generates distinct editing outcomes in bacteria and eukaryotes compared to deaminase and glycosylase base editing. Editors with deaminases include Adenine Base Editors (ABEs)⁷⁴ and Cytosine Base Editors (CBEs)⁷⁵, while editors with glycosylases include A-to-Y Base Editor (AYBE)³⁶, Glycosylase Base Editors (GBEs)⁷⁶, Adenine transversion Base Editor (AXBE)⁷⁷, Glycosylase-based Guanine Base Editors (gGBEs/GYBE)⁷⁸, Glycosylase-based Thymine Base Editors (gTBEs), Glycosylase-based Cytosine Base Editors (gCBEs)⁴⁰, Deaminase-Free Thymine Base editor (DAF-TBE), Deaminase-Free Cytosine Base Editor (DAF-CBE)³⁸, Thymine DNA glycosylase based editor (TDG), Cytosine DNA glycosylase based editor (CDG)³⁷, Thymine base Editor (TBEs)³⁹. RT: repair template. HDR: homology-directed repair. Nucleotides representing edits are colored to help compare the glycosylation and ADP-ribosylation of thymine.










Base modification


Tested bacteria

Tested eukaryotes

Deamination



Glycosylation



ADP-ribosylation

